Irinotecan, anlotinib, and pembrolizumab-like drug for advanced colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests adding anlotinib and penpulimab to irinotecan for colorectal cancer that has come back or spread after earlier chemotherapy. It may help shrink tumors and control the disease when standard first-line treatment no longer works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colon cancer that has spread or come back (confirmed by biopsy).
- You previously had oxaliplatin plus a 5-FU–type medicine (like 5-FU, capecitabine, or S-1) as first treatment, and it stopped working within a set time window.
- Your scan shows at least one measurable tumor spot on CT (size thresholds apply).
- Your tumor is required to be BRAF wild type; the study also uses MSS/pMMR for at least one group.
- Your health status is good enough for treatment (performance status ECOG 0–1) and you have enough blood, liver, and kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of chemotherapy (irinotecan liposomes) as a first treatment for metastatic colorectal cancer that has not been treated before. It focuses on patients with specific genetic changes (RAS or BRAF V600E mutation) or right-sided colon cancer, and looks at how well the drug works.
This Phase 2 trial tests whether adding cetuximab to irinotecan can control metastatic colorectal cancer that has returned or worsened after standard treatments. It targets people whose tumor is left-sided and shows “wild-type” RAS and BRAF genes on blood testing after prior therapy.
This trial tests a new drug combination for colorectal cancer that has spread to other parts of the body and did not respond to or could not tolerate standard first-line chemotherapy. The goal is to see if this new approach can help shrink the cancer and extend survival.
This Phase 2 trial tests an individualized treatment chosen from your tumor’s lab testing (genetic and RNA profile plus a drug-sensitivity test from your tumor cells). It may help by matching you to targeted anti-cancer drugs that are most likely to work for your specific cancer.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.